Edition:
India

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

5.90USD
30 Oct 2020
Change (% chg)

$-0.08 (-1.34%)
Prev Close
$5.98
Open
$5.97
Day's High
$6.02
Day's Low
$5.73
Volume
213,225
Avg. Vol
214,463
52-wk High
$6.30
52-wk Low
$2.21

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2019 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATES.Q3 LOSS PER SHARE $0.14.CASH AND CASH EQUIVALENTS OF $21.2 MILLION AT JUNE 30, 2019, COMPARED TO $22.9 MILLION AT SEPTEMBER 30, 2018.  Full Article

Anavex Life Sciences Corp Files Prospectus Supplement Relates To Issuance, Sale Of Up To $21.2 Mln In Common Shares
Thursday, 13 Jun 2019 

June 12 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO $21.2 MILLION IN COMMON SHARES TO LINCOLN PARK CAPITAL FUND LLC.  Full Article

Anavex Life Sciences Reports Q2 Results
Wednesday, 8 May 2019 

May 8 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL 2019 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATES.Q2 LOSS PER SHARE $0.17.CASH AND EQUIVALENTS OF $19.5 MILLION AT MARCH 31, 2019, COMPARED TO $22.9 MILLION AT SEPTEMBER 30, 2018..  Full Article

Anavex Life Sciences Cash And Equivalents $22.9 Mln At Sept. 30
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATE.ANAVEX LIFE SCIENCES CORP - CASH AND EQUIVALENTS OF $22.9 MILLION AT SEPTEMBER 30, 2018, COMPARED TO $27.4 MILLION AT SEPTEMBER 30, 2017.  Full Article

BRIEF-Anavex Life Sciences Announces First Participant Enrolled In Phase 1 Study Of Anavex 3-71

* ANAVEX LIFE SCIENCES ANNOUNCES FIRST PARTICIPANT ENROLLED IN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage: